Metabolic Syndrome and Long-term Survival Following Liver Resection

Completed

• Conditions: Survival

• Registration Number: NCT05568576
• Lead Sponsor: Assiut University

Brief Summary

Although hepatitis C virus (HCV) infection remains one of the main causes of hepatocellular carcinoma (HCC) worldwide, metabolic syndrome, with its increase in prevalence, has become an important and significant risk factor for HCC

Detailed Description

Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide. In Egypt, it represents the fourth common cancer. Many hospital-based studies reported increasing the incidence of HCC. The reason for increased incidence could be attributed to (1) improvement in screening programs and diagnostic tools, (2) increasing the survival rate of cirrhotic patients that increases the chance of developing HCC, and (3) increasing the incidence and complications of hepatitis C virus (HCV) which is the most important risk factor in developing liver cancer including HCC in Egypt Precise staging of HCC initially is very useful for determination of the therapeutic options and the overall prognosis of the disease. There are certain clinical features upon which most staging systems use for HCC assessment. These clinical features are size and local extent of the tumor, metastasis of the tumor, severity of the liver disease, and the overall patient performance status Several studies in the United States, Europe, Taiwan, Hong Kong , and New Zealand have examined the potential relationships between various metabolic factors and HCC risks, mostly focusing on type 2 DM and obesity. Diabetes , or even prediabetes, has been observed to be a major metabolic factor related to an increased risk of HCC in individuals with HBV infections.

There is paucity in literature about effect of metabolic syndrome on Long-term Survival Following Liver Resection for Hepatocellular Carcinoma Among Patients With Chronic Hepatitis C Virus Infection

Study Timeline

• Study Start: 2015-01-01
• Study First Submitted: 2022-10-02
• Study First Submitted QC: 2022-10-02
• Study First Posted: 2022-10-05
• Primary Completion: 2022-12-30
• Study Completion: 2022-12-30
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-04
• Last Update Posted: 2023-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• All patients with HCC secondary to HCV infection underwent hepatic resection

Exclusion Criteria

HBV patients other modalities of therapy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival	between two and five years	assess frequency long term survival after resection

Trial Locations

Locations (1)

Ahmed Mohammed Abu-Elfatth; 🇪🇬 Assiut, Egypt